TRS-005

N/A

Report date: 2025/07/09 11:08:13

Base Information

Drug NameTRS-005

Drug Alias Name注射用TRS005TRS-005

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > VC linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MMAE payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionAnti-CD20Tubulin polymerisation inhibitors

TargetsB-lymphocyte antigen CD20Tubulin

Therapy Area/IndicationsLymphoma, Large B-Cell, DiffuseLymphoma, B-CellLymphoma, Non-Hodgkin

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaPhase 2 Clinical

Originator CompaniesZhejiang Teruisi Pharmaceutical Inc

China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesZhejiang Teruisi Pharmaceutical Inc

Inactive CompaniesN/A

Active IndicationsLymphoma, Large B-Cell, DiffuseLymphoma, B-CellLymphoma, Non-Hodgkin

Inactive IndicationsN/A

Other Information

ATC CodeN/A